NEREUS™, first new motion sickness drug in 40 years, now available in the US with direct-to-consumer ordering.

Vanda Pharmaceuticals has launched NEREUS™ (tradipitant), the first new prescription drug in over 40 years for preventing motion sickness-induced vomiting in adults. Approved by the FDA in December 2025, NEREUS™ works by blocking NK-1 receptors in the brain to stop vomiting triggered by motion. It is available nationwide through pharmacies and a direct-to-consumer platform at nereus.us, offering a discounted price of $85 per dose compared to the standard $255. This new treatment addresses a common condition affecting up to 30% of American adults during travel and represents a significant advancement in motion sickness care.